Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the rates of seroconversion to a hepatitis
B vaccine series after a single 750 mg intravenous (IV) dose of vedolizumab or placebo.
Secondary objectives are to determine the rates of seroconversion to an oral cholera vaccine
series, assess change in anti-hepatitis B surface antibodies and assess the safety and
tolerability of a single 750-mg IV dose of vedolizumab.